The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder

Sylvia Bellucci; Bruno Cassinat; Nadine Bonnin; Christophe Marzac; Isabelle Crassard

doi:10.1160/TH08-02-0081

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 99(06): 1119-1120
DOI: 10.1160/TH08-02-0081

Letters to the Editor

Schattauer GmbH

The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder

Sylvia Bellucci

¹AP-HP, Hôpital Lariboisière, Service d’Hématologie biologique, Paris France

²Université Paris, Faculté de Médecine, Paris France

,

Bruno Cassinat

³AP-HP, Hôpital Saint Louis, Unité de Biologie Cellulaire, Paris France

,

Nadine Bonnin

³AP-HP, Hôpital Saint Louis, Unité de Biologie Cellulaire, Paris France

,

Christophe Marzac

⁴AP-HP Hôpital Saint-Antoine, Service d’immunologie et hématologie biologiques, Paris, France

,

Isabelle Crassard

⁵AP-HP, Hôpital Lariboisière, Service de Neurologie, Paris France

References
1 Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-2466.
2 Gruppo Italiano Studio Policitemia. Polycythemia Vera: the natural history of 1213 patients follow up for 20 years. Ann Int Med 1995; 123: 656-664
3 Bazzan M, Tamponi G, Schinco P. et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999; 78: 539-543.
4 Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6: 162-170.
5 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders : prevalence, prognostic factors and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-320
6 Campbell PJ, Scott LM, Buck G. et al. and the United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
7 Randi ML, Lombardi AM, Scapin M. et al. Haemostatic proteins gene polymorphisms in patients with unusual vein thrombosis and Ph-myeloproliferative disorders. Thromb Haemost 2007; 98: 702-704.
8 Colaizzo D, Amitrano L, Tiscia GL. et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61.
9 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.
10 Tefferi A, Thiele J, Orazi A. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
11 Kiladjian JJ, Cassinat B, Turlure P. et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037-2040.
12 Ferro JM, Canhão P, Stam J. et al. and the ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-670.